Skip to main content
Rizobacter Argentina S.A. logo

Rizobacter Argentina S.A. — Investor Relations & Filings

ISIN · AR0065093756 BYMA Manufacturing
Open in API
Filings indexed 1,120 across all filing types
Latest filing 2026-06-05 Capital/Financing Update
Country AR Argentina
Listing BYMA

About Rizobacter Argentina S.A.

https://rizobacter.com.ar/en/argentina

Rizobacter is a leading agricultural biosolutions company that researches, develops, and commercializes innovative products for sustainable crop growth. Specializing in biologicals, its comprehensive portfolio includes inoculants, biostimulants, seed treatments, adjuvants, biocontrol agents, and crop nutrition solutions. Notably, Rizobacter is a global leader in soybean inoculants. The company's sustainable biological solutions enhance crop productivity, drive higher yields, and contribute to global food security, leveraging a unique biotech platform with patented technologies for microbial ag-inputs.

Recent filings

Filing Released Lang Actions
INFORMACIÓN RELEVANTE RELATIVA A INSTRUMENTOS - LA SOCIEDAD PUBLICÓ LAS ADENDAS A LOS SUPLEMENTOS DE PROSPECTO DE LAS OBLIGACIONES NEGOCIABLES SERIE IX Y DE LAS OBLIGACIONES NEGOCIABLES SERIE X
Capital/Financing Update Classification · 90% confidence The document is a letter from the company’s president to the securities commission and stock exchange announcing the publication of addenda to the prospectus supplements for its Series IX and X negotiable obligations, following approval of required majorities in a debt exchange offer and consent solicitation. This concerns a modification to the terms of outstanding debt instruments, which fits squarely under financing and capital structure updates. Therefore, it should be classified as a Capital/Financing Update.
2026-06-05 Spanish
INFORMACIÓN RELEVANTE RELATIVA A INSTRUMENTOS - RESULTADO DE LA OFERTA DE CANJE Y SOLICITUD DE CONSENTIMIENTO OBLIGACIONES NEGOCIABLES SERIES IX Y X
Capital/Financing Update Classification · 85% confidence The document is an announcement by Rizobacter Argentina S.A. to regulatory authorities informing investors that the company has completed an exchange offer and consent solicitation for its Series IX and X debt obligations, achieving the required participation level. This is a financing activity (debt exchange) impacting the company’s capital structure. Under the definitions, such updates fall under “Capital/Financing Update” (CAP), not merely a regulatory notice (RNS).
2026-05-29 Spanish
INFORMACIÓN RELEVANTE RELATIVA A INSTRUMENTOS - INFORMA PUBLICACIÓN DE ADENDA Y AVISO ACLARATORIO Y PRÓRROGA DE OFERTA DE CANJE Y SOLICITUD DE CONSENTIMIENTO
Capital/Financing Update Classification · 85% confidence The document is a notice from Rizobacter Argentina S.A. informing the CNV and exchanges that it has published an addendum and clarifying notice related to its debt exchange offer (Oferta de Canje y Solicitud de Consentimiento Obligaciones Negociables). This is a financing activity update concerning the company’s capital structure and consent solicitation for its negotiable obligations. It is not a full report, audit, or earnings release, but rather a specific financing update.
2026-05-26 Spanish
NORMA CONTABLE: NIIF - TIPO BALANCE: INDIVIDUAL - PERIODICIDAD: 3 - FECHA CIERRE: 2026-03-31 - ESTADOS CONTABLES - NIIF
Interim / Quarterly Report Classification · 95% confidence The document is titled “Estados Financieros Separados Condensados Intermedios” and covers the period of nine months ended 31 March 2026. It contains full interim financial statements (income statement, balance sheet, statement of changes in equity, cash flows) and related notes. This is not a brief announcement but the actual interim financial report, fitting the definition of an Interim/Quarterly Report. 9M 2026
2026-05-12 Spanish
NORMA CONTABLE: NIIF - TIPO BALANCE: CONSOLIDADO - PERIODICIDAD: 3 - FECHA CIERRE: 2026-03-31 - ESTADOS CONTABLES - NIIF
Interim / Quarterly Report Classification · 92% confidence The document contains detailed consolidated interim financial statements (income statement, balance sheet, cash flows, notes) for the nine-month period ended 31 March 2026, along with management commentary and auditor’s report. It is a comprehensive financial report for a period shorter than a full fiscal year, satisfying the criteria for an Interim/Quarterly Report rather than an earnings highlight or mere announcement. Therefore, it should be classified as an Interim/Quarterly Report. 9M 2026
2026-05-12 Spanish
FEC. CELEB.: 11-05-2026 - TEMA: 5 - ACTA DE ÓRGANO DE ADMINISTRACIÓN (DIRECTORIO)
Regulatory Filings Classification · 72% confidence The document is a set of minutes (“Acta”) of a Board of Directors meeting where the board formally approves the interim condensed consolidated and separate financial statements as of March 31, 2026. It does not include any actual financial data, tables, or narrative analysis—it merely references the interim financial statements, notes they were reviewed, and records the unanimous approval. Under the “menu vs meal” rule, this is not the interim report itself (IR) since substantive financial content is omitted, and it is not an earnings release or an investor presentation. Nor is it a change in management, dividend notice, or any other specific category. It appears to be a regulatory submission of board minutes, which best fits the fallback “Regulatory Filings” category (RNS).
2026-05-12 Spanish

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.